<DOC>
	<DOCNO>NCT01199289</DOCNO>
	<brief_summary>The purpose study determine AMG 827 effective compare placebo measure change Asthma Control Questionnaire ( ACQ ) composite score .</brief_summary>
	<brief_title>A Study Evaluate Dosing AMG 827 Subjects With Inadequately Controlled Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Men woman 18 65 year age Percent predict FEV1 ≥ 50 % ≤ 80 % At least 12 % reversibility prebronchodilator FEV1 Inhaled corticosteroid ( ICS ) ≥ 200 ≤ 1000 µg/day fluticasone equivalent . Ongoing asthma symptom ACQ composite score ≥ 1.5 point Respiratory infection within 4 week screen visit 1 week baseline visit History chronic obstructive pulmonary disease chronic pulmonary condition asthma Any uncontrolled clinically significant systemic disease ( eg , uncontrolled diabetes , liver disease )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Amgen</keyword>
	<keyword>chronic inflammatory disease</keyword>
	<keyword>wheeze</keyword>
</DOC>